Search Results
76 items found for "Keltic Pharma Therapeutics"
- Ep 79 with Dr. Graeme Milligan
Milligan is the co-founder of both Caldan Therapeutics (2015) which discovers novel therapeutics for and other indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics (2020) which is developing new treatments for malaria.
- Ep 80 with Dr. Andrew Tobin
The vehicle by which Andrew is translating fundamental findings to commercial products is Keltic Pharma Therapeutics Ltd , a biotechnology company co-founded by Andrew with series A funding from the European
- Ep 00 with Dr. Yamina Berchiche
GPCR Ecosystem, with the goal is to bring together GPCR scientists, biotech, and pharma leaders as well
- Ep 117 with Dr. Pierre Eftekhari
creation of Inoviem scientific in Nov. 2011 by myself we have been regularly working with GPCRs for our pharma
- Ep 152 with Dr Arthur Christopoulos
Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics They explored the evolution of the field, allosteric modulation concepts, and potential therapeutic approaches Arthur will work on designing ligands for specific receptors, aiming to create biased agonists for therapeutic Yamina discussed the potential of autoantibodies and allosteric modulation in the context of disease and therapeutic endogenous allosteric ligands and the possibility of using a neutral allosteric ligand as a preferred therapeutic
- Ep 48 with Dr Nyla Naim Dr Michael Lemieux Dr Jason Nasse from Addgene
Prior to his role at Addgene, Jason held roles in academia, big pharma, and non-profit research organizations
- Noval insights and therapeutic strategies for tumor-induced kidney pathologies
< GPCR News < GPCRs in Oncology and Immunology Noval insights and therapeutic strategies for tumor-induced receptor (TACR3), a homolog of the G protein-coupled receptor TkR99D in fruit flies, as a potential therapeutic The implications of these findings for transforming the therapeutic approaches to renal complications These insights could contribute to the advancement of diagnostic and therapeutic strategies for treating
- Session III | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
technology for high-throughput screening of pharmacological compound libraries to identify potential therapeutic "Ana Lilia Moreno Salinas (2), Arturo Mancini (1), Raida Jallouli (2), Richard Leduc (2) (1)Domain Therapeutics drug discovery of small molecules for the treatment of inflammatory disorders and cancer at Paraza Pharma Laurent Sabbagh on the web Domain Therapeutics Characterizing hADGRE5/CD97 Activation and Signaling: Domain Therapeutics North America Inc., Montreal, Quebec, Canada 3.
- Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Vulnerability in Ovarian Cancer
Sponsors GPCR Retreat Program < Back to schedule Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Several of these targets are being developed for potential new therapeutic strategies in ovarian and
- Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers
< GPCR News < GPCRs in Oncology and Immunology Expanding role of CXCR2 and therapeutic potential of CXCR2 date, many small-molecule CXCR2 antagonists have entered clinical trials, showing favorable safety and therapeutic
- Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms and therapeutic targets in atopic diseases
Oncology and Immunology Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms and therapeutic
- Dr. GPCR Summit 2021 | Dr. GPCR Ecosystem
Everyone is welcome to present their work (students, postdocs, PI's, biotech, pharma companies)!
- Ep 151 with Dr GPCR Board
Waldhoer "I am a pharmacologist with a ~30 years background in academia and industry, working both in big pharma
- Expression pattern and clinical significance of beta 2-adrenergic receptor in oral squamous cell carcinoma: an emerging prognostic indicator and future therapeutic target
2-adrenergic receptor in oral squamous cell carcinoma: an emerging prognostic indicator and future therapeutic
- Ep 98 with Dr. GPCR Team
< Back to podcast list Inês Pinheiro, Monserrat Avila Zozaya & Yamina Berchiche About Inês Pinheiro PharmD
- Ep 122 with Dr. Nicolas Gilles
He is pioneering the investigation of animal toxins acting on GPCRs, the largest therapeutic target class His strongest expertise lies in therapeutic target identification and all the steps from venom manipulations pharmacological properties of these new ligands are deemed exceptional, a lead optimization is realized and its therapeutic
- C-Principles2 (List) | Dr. GPCR Ecosystem
essential additional elements to GPCR discovery programs that extend the discovery process and increase therapeutic November 7th: Drug Disposition in Physiological Tissues as a Therapeutic Variable. December 5th: Unique Exploitable GPCR-Ligand Behaviors for Therapeutic Benefit. Learn how to therapeutically exploit GPCRs (Physiology’s ‘Swiss Army Knife’) wide repertoire of ways Adjust ligand kinetics and tissue disposition for optimal therapeutic activity.
- Ep 81 with Dr. Christel Menet
I then started my career at Evotec before moving to Domain Therapeutics (called Faust pharmaceutical chemistry. 6 years ago I decided to take on a new challenge by taking the position of CSO at Confo Therapeutics Christel Menet on the web Hyphen Projects GPCRS Drug Discovery Confo Therapeutics LinkedIn Dr.
- Ep 95 with Chris Langmead
collaborative neuroscience R&D program with Servier (France) and is the co-founder and CEO of Phrenix Therapeutics , a biotech spin-out from the Neuromedicines Discovery Centre that is developing next-generation therapeutics Prior to these roles this he was Head of Pharmacology at Heptares Therapeutics Ltd., a UK-based biotechnology These successes enabled the US$400M sale of Heptares Therapeutics Ltd. to the Sosei Group Corporation
- Ep 42 with Dr. Randy Hall
Randy has received a number of research prizes, including the PhRMA New Investigator Award, the Distinguished
- Ep 107 with Dr. Roger Sunahara
bases for ligand binding and efficacy to help optimize the design and engineering of more efficacious therapeutics perspective in the pursuit of receptor subtype-specific ligands, a major aspect to achieve safer, on-target therapeutics The Sunahara lab has also been developing protein-based therapeutics using structure-guided design and A notable therapeutic is an enzyme that hydrolyzes cocaine. as a treatment for cocaine abuse, a debilitating disease that would require long-term and sustained therapeutic
- From odor to oncology: non-canonical odorant receptors in cancer
These findings shed light on the potential of non-canonical odorant receptors as therapeutic targets these chemoreceptors and various types of cancer, potentially paving the way for innovative odor-based therapeutics Ultimately, this review discusses the potential development of novel therapeutic strategies targeting
- GPCR Retreat 2023 - Part II
He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic Maddi is currently a second year Ph.D. student in the Molecular Pharmacology and Therapeutics (MPaT)
- Regulator of G protein signaling 16 restrains apoptosis in colorectal cancer through disrupting TRAF6-TAB2-TAK1-JNK/p38 MAPK signaling
cancer (CRC) remains a major global cause of cancer-related mortality, lacking effective biomarkers and therapeutic Revealing the critical pathogenic factors of CRC and the underlying mechanisms would offer potential therapeutic proteins in CRC, identifying Regulator of G protein signaling 16 (RGS16) as a prospective diagnostic and therapeutic
- Ep 63 with Dr. Khaled Abdelrahman
He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics
- Olfactory Receptors and Tumorigenesis: Implications for Diagnosis and Targeted Therapy
The potential for precise tumor diagnosis and targeted therapy through therapeutic targeting of olfactory Tang, Ye Tian, Chun-Xia Zhang, Guo-Tai Wang Tags G Protein-coupled receptors , Olfactory receptors , Therapeutic
- Ep 109 with Dr. Katarina Nemec
I aim to discover new therapeutic approaches, and druggable molecules or refine canonical drug targets while performing various cell-based experiments to understand the binding, activation, and signaling of therapeutically
- Ep 92 with Dr. Stephane Angers
He is the scientific founder of two biotech companies, ModMab Therapeutics , and AntlerA Therapeutics